Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (NEXT-CAT)

25 de setembro de 2026 atualizado por: Eun Kyoung Kim, Samsung Medical Center

Net Adverse Clinical Events With EdoXaban Versus Apixaban Treatment in Cancer-Associated Thrombosis

This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous thromboembolism (CAT). A total of 2,300 patients with active cancer and objectively confirmed venous thromboembolism will be randomized in a 1:1 ratio to receive edoxaban-based or apixaban-based treatment. The primary objective is to determine whether edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to net adverse clinical events (NACE), defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria.

Visão geral do estudo

Status

Ainda não está recrutando

Descrição detalhada

Cancer-associated thrombosis (CAT) is an important cause of morbidity and mortality in patients with active cancer. Patients with CAT are at increased risk of both recurrent venous thromboembolism and bleeding during anticoagulant treatment, making the balance between efficacy and safety particularly important when selecting an anticoagulant.

Non-vitamin K antagonist oral anticoagulants have become established treatment options for CAT. Edoxaban and apixaban are both factor Xa inhibitors with demonstrated efficacy and safety in patients with CAT. However, they have been evaluated separately against low-molecular-weight heparin, and direct randomized comparisons between edoxaban and apixaban are lacking. The two agents also differ in dosing frequency, dose-reduction strategies, pharmacokinetic characteristics, and renal elimination. Whether these differences translate into differences in overall clinical outcomes in patients with CAT remains uncertain.

NEXT-CAT is a prospective, multicenter, randomized, open-label, blinded-endpoint trial designed to directly compare edoxaban-based treatment with apixaban-based treatment in patients with active cancer and objectively confirmed venous thromboembolism. A total of 2,300 participants will be randomized in a 1:1 ratio, with randomization stratified by participating center and the presence of gastrointestinal cancer at baseline.

The primary hypothesis is that edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to the incidence of net adverse clinical events (NACE). The primary endpoint is a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria. Participants will be followed at 1, 3, 6, 9, 12, and 18 months after randomization and annually thereafter, with follow-up continuing until 1 year after enrollment of the last participant.

Clinical events corresponding to the primary and secondary endpoints will be evaluated by an independent Clinical Event Adjudication Committee blinded to treatment allocation.

Tipo de estudo

Intervencional

Inscrição (Estimado)

2300

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Busan, Coréia do Sul
        • Dong-A University Hospital
        • Contato:
          • Sung-Hyun Kim
        • Investigador principal:
          • Sung-Hyun Kim, MD, PhD
      • Goyang, Coréia do Sul
        • Inje University Ilsan Paik Hospital
        • Contato:
          • Min Sun Kim
        • Investigador principal:
          • Min Sun Kim
      • Gwangmyeong, Coréia do Sul
        • Chung-Ang University Gwangmyeong Hospital
        • Contato:
          • Eun Jeong Cho
        • Investigador principal:
          • Eun Jeong Cho
      • Hwasun, Coréia do Sul
        • Chonnam National University Hwasun Hospital
        • Contato:
          • Hyukjin Park
        • Investigador principal:
          • Hyukjin Park
      • Jeonju, Coréia do Sul
        • Chonbuk National University Hospital
        • Contato:
          • Ho-Young Yhim
        • Investigador principal:
          • Ho-Young Yhim, MD, PhD
      • Seoul, Coréia do Sul
        • Kangbuk Samsung Hospital
        • Contato:
          • Jiwon Kim
        • Investigador principal:
          • Jiwon Kim
      • Seoul, Coréia do Sul
        • Korea University Anam Hospital
        • Contato:
          • So Ree Kim
        • Investigador principal:
          • So Ree Kim
      • Seoul, Coréia do Sul
        • Samsung Medical Center
        • Subinvestigador:
          • Se-Hoon Lee, MD, PhD
        • Subinvestigador:
          • Taek Kyu Park, MD, PhD
        • Contato:
        • Investigador principal:
          • Eun Kyoung Kim, MD, PhD
        • Subinvestigador:
          • David Hong, MD, PhD
      • Seoul, Coréia do Sul
        • Seoul National University Hospital
        • Contato:
          • Sang-Hoon Na, MD, PhD
        • Investigador principal:
          • Sang-Hoon Na, MD, PhD
      • Seoul, Coréia do Sul
        • Konkuk University Medical Center
        • Contato:
          • Ji-Won Hwang
        • Investigador principal:
          • Ji-Won Hwang
      • Seoul, Coréia do Sul
        • Seoul St. Mary's Hospital
        • Contato:
          • Mi-Hyang Jung
        • Investigador principal:
          • Mi-Hyang Jung, MD, PhD
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Coréia do Sul
        • National Cancer Center
        • Contato:
          • Mi-Hyang Kwak
        • Investigador principal:
          • Mi-Hyang Kwak

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

19 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Age ≥19 years.

  2. Objectively confirmed symptomatic or incidentally detected venous thromboembolism (VTE), including:

    • Proximal deep vein thrombosis (DVT)
    • Pulmonary embolism (PE)
    • Both DVT and PE.
  3. Any type of active cancer, defined by at least one of the following:

    • Cancer diagnosed within the previous 6 months
    • Locally advanced or metastatic cancer
    • Receipt of cancer-directed therapy (chemotherapy, immunotherapy, targeted therapy, endocrine therapy, radiotherapy, or cancer surgery) within the previous 6 months
    • Cancer not in complete remission at the time of enrollment
    • Ongoing cancer treatment or residual cancer.
  4. Ability to understand the risks, benefits, and treatment alternatives of the study and to voluntarily provide written informed consent.

Exclusion Criteria:

  1. Known hypersensitivity or contraindication to either study drug (edoxaban or apixaban).
  2. Severe renal impairment (creatinine clearance <15 mL/min) or dialysis.
  3. Active major bleeding.
  4. An indication requiring alternative anticoagulation, such as a mechanical heart valve or moderate-to-severe mitral stenosis.
  5. Antiphospholipid syndrome.
  6. Life expectancy <6 months due to cancer progression or comorbid conditions, or anticipated poor treatment adherence, as determined by the investigator.
  7. Pregnancy or breastfeeding.
  8. Moderate or severe hepatic impairment classified as Child-Pugh class B or C.
  9. Thrombocytopenia with a platelet count <50,000/mm³.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Edoxaban-based Treatment

Participants randomized to this arm will receive oral edoxaban once daily. The standard dose is 60 mg once daily, with dose reduction according to the protocol based on renal function, body weight, concomitant P-glycoprotein inhibitors, and other prespecified clinical factors.

Edoxaban is administered orally once daily. The standard dose is 60 mg once daily. The dose is reduced to 30 mg once daily in participants with a creatinine clearance of 15-50 mL/min, body weight ≤60 kg, or concomitant use of specified P-glycoprotein inhibitors. In participants aged ≥80 years who are considered at high risk of bleeding and meet the prespecified criteria, further dose reduction to 15 mg once daily may be considered.

Comparador Ativo: Apixaban-based Treatment

Participants randomized to this arm will receive oral apixaban twice daily. The standard dose is 5 mg twice daily, with dose reduction to 2.5 mg twice daily according to the prespecified dose-reduction criteria in the protocol.

Apixaban is administered orally at a standard dose of 5 mg twice daily. The dose is reduced to 2.5 mg twice daily in participants who meet the prespecified dose-reduction criteria, including those who meet at least two of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, or those with severe renal impairment with a creatinine clearance of 15-29 mL/min.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Net Adverse Clinical Events (NACE)
Prazo: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of a net adverse clinical event, defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria.

From randomization until 1 year after enrollment of the last participant

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Recurrent Venous Thromboembolism or Venous Thromboembolism-related Death
Prazo: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of recurrent venous thromboembolism or venous thromboembolism-related death.

From randomization until 1 year after enrollment of the last participant
Recurrent Venous Thromboembolism
Prazo: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of objectively confirmed recurrent venous thromboembolism, including recurrent deep vein thrombosis or recurrent pulmonary embolism.

From randomization until 1 year after enrollment of the last participant
Venous Thromboembolism-related Death
Prazo: From randomization until 1 year after enrollment of the last participant

Death resulting from objectively confirmed fatal pulmonary embolism, recurrent venous thromboembolism directly leading to death, or unexplained death for which no alternative cause is identified and which is adjudicated as venous thromboembolism-related by the Clinical Event Adjudication Committee.

From randomization until 1 year after enrollment of the last participant
Major Bleeding According to International Society on Thrombosis and Haemostasis Criteria
Prazo: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of major bleeding according to International Society on Thrombosis and Haemostasis criteria, including fatal bleeding, symptomatic bleeding in a critical area or organ, bleeding causing a decrease in hemoglobin of at least 2 g/dL, or bleeding requiring transfusion of at least 2 units of whole blood or packed red blood cells.

From randomization until 1 year after enrollment of the last participant
Clinically Relevant Non-major Bleeding
Prazo: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of clinically relevant non-major bleeding, defined as clinically overt bleeding that does not meet the criteria for major bleeding but leads to hospitalization or an increased level of care, medical or surgical treatment, or a change in antithrombotic therapy.

From randomization until 1 year after enrollment of the last participant
Clinically Relevant Bleeding
Prazo: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of clinically relevant bleeding, defined as a composite of major bleeding or clinically relevant non-major bleeding.

From randomization until 1 year after enrollment of the last participant
Broad Net Adverse Clinical Events
Prazo: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of a broad net adverse clinical event, defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, major bleeding, or clinically relevant non-major bleeding.

From randomization until 1 year after enrollment of the last participant
All-cause Mortality
Prazo: From randomization until 1 year after enrollment of the last participant

Death due to any cause occurring during the study follow-up period.

From randomization until 1 year after enrollment of the last participant
Permanent Discontinuation Due to Adverse Events
Prazo: From randomization until 1 year after enrollment of the last participant

Permanent discontinuation of the assigned study drug due to any adverse event during follow-up.

From randomization until 1 year after enrollment of the last participant

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de novembro de 2026

Conclusão Primária (Estimado)

31 de dezembro de 2029

Conclusão do estudo (Estimado)

31 de dezembro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

25 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

25 de setembro de 2026

Primeira postagem (Real)

1 de outubro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

1 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

25 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

De-identified individual participant data that underlie the results reported in the main publication may be shared with qualified researchers upon reasonable request.

Prazo de Compartilhamento de IPD

Beginning after publication of the main study results; no predetermined end date.

Critérios de acesso de compartilhamento IPD

Data may be made available to qualified researchers upon reasonable request for scientifically appropriate research purposes. Requests will be reviewed by the principal investigator and the study steering committee based on the scientific merit and appropriateness of the proposed research and data-use plan. Data sharing will be conducted in accordance with applicable regulations and participant privacy requirements.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever